- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04809363
Een studie van CDPATH™ om de ziekte van Crohn te helpen beheersen en behandelen (COMPASS-CD)
Een fase 4-onderzoek ter evaluatie van het gebruik in de praktijk van CDPATH™, een risicovoorspellingsinstrument voor de ziekte van Crohn
CDPATH™ is a tool to help predict the potential for developing Crohn's disease related complications in certain adult participants within 3 years. The main aim of the study is to explore the use of CDPATH™ to describe a participant's risk profile and to have discussions with their doctor about the potential path of their Crohn's disease. The number of visits will be decided by the study clinic according to their standard practice.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The tool being tested in this study is called CDPATH™. CDPATH™ is being used to provide a graphical representation of an individual participant's risk of developing a CD-related complication within three years, leveraging known participant risk factors based on clinical, serologic and genetic variables to help people categorize risk who have CD. This study will gather data on the use of the tool in real-world settings to inform practical use of CDPATH™.
The study will enroll approximately 200 patients. Participants and health care providers (HCPs) will be surveyed to understand their satisfaction with the CDPATH™ process and with their treatment choice.
This multi-center trial will be conducted in the United States. The overall time to participate in this study is 36 months. Participants will make multiple visits to the HCP's clinic, and data will be collected approximately every six months up to 3 years, based on the timing of routine follow-up appointments for assessment.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 4
Contacten en locaties
Studie Locaties
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85032
- Arizona Arthritis & Rheumatology Research, PLLC
-
-
California
-
Loma Linda, California, Verenigde Staten, 92357
- VA Loma Linda Healthcare System
-
Murrieta, California, Verenigde Staten, 92563
- United Medical Doctors
-
Newport Beach, California, Verenigde Staten, 92663
- University of Southern California Medical Center
-
Orange, California, Verenigde Staten, 92868
- University of California at Irvine Medical Center
-
Orange, California, Verenigde Staten, 92868
- Clinnova Research Solutions
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80014
- Kaiser Permanate of Colorado
-
-
Connecticut
-
Hamden, Connecticut, Verenigde Staten, 06518
- Medical Research Center of Connecticut, LLC
-
-
Florida
-
Clearwater, Florida, Verenigde Staten, 33762
- West Central Gastroenterology d/b/a Gastro Florida
-
Pensacola, Florida, Verenigde Staten, 32503
- Gastroenterology Associates of Pensacola, PA
-
-
Idaho
-
Idaho Falls, Idaho, Verenigde Staten, 83404
- Grand Teton Research Group, PLL
-
-
Illinois
-
Arlington Heights, Illinois, Verenigde Staten, 60005
- GI Alliance
-
Gurnee, Illinois, Verenigde Staten, 60031
- GI Alliance
-
Northbrook, Illinois, Verenigde Staten, 60062
- Comprehensive Gastrointestinal Health
-
Rockford, Illinois, Verenigde Staten, 61107
- Rockford Gastroenterology Associates, Ltd.
-
-
Indiana
-
Indianapolis, Indiana, Verenigde Staten, 46202
- Indiana University
-
-
Iowa
-
Clive, Iowa, Verenigde Staten, 50325
- Iowa Digestive Disease Center
-
Iowa City, Iowa, Verenigde Staten, 52242-1009
- University of Iowa Hospitals & Clinics
-
-
Kansas
-
Kansas City, Kansas, Verenigde Staten, 66160
- University of Kansas Medical Center Research Institute, Inc.
-
-
Louisiana
-
Baton Rouge, Louisiana, Verenigde Staten, 70809
- GI Alliance - Baton Rouge
-
Shreveport, Louisiana, Verenigde Staten, 71105
- Louisiana Research Center, LLC
-
-
Maryland
-
Columbia, Maryland, Verenigde Staten, 21045
- Gastro Center of Maryland
-
-
Massachusetts
-
Burlington, Massachusetts, Verenigde Staten, 01805
- Lahey Clinic Inc. - PARENT ACCOUNT
-
Worcester, Massachusetts, Verenigde Staten, 01655
- UMASS Memorial Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, Verenigde Staten, 87131-0001
- University of New Mexico
-
-
New York
-
New York, New York, Verenigde Staten, 10075-1850
- Lenox Hill Hospital
-
-
Ohio
-
Beavercreek, Ohio, Verenigde Staten, 45431
- Clinical Inquest Center Ltd
-
Dayton, Ohio, Verenigde Staten, 45415
- Dayton Gastroenterology, Inc
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97220-9442
- The Oregon Clinic, P.C.
-
-
Pennsylvania
-
Camp Hill, Pennsylvania, Verenigde Staten, 17011
- Susquehanna Research Group, LLC
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15213
- University of Pittsburgh Medical Center Health System
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15212
- Allegheny Center for Digestive Health
-
Uniontown, Pennsylvania, Verenigde Staten, 15401
- Frontier Clinical Research, LLC
-
-
South Carolina
-
Summerville, South Carolina, Verenigde Staten, 29486
- Palmetto Primary Care Physician Division of Gastroenterology
-
-
South Dakota
-
Rapid City, South Dakota, Verenigde Staten, 57701
- Rapid City Medical Center, LLC
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37204
- Vanderbilt University Medical Center
-
-
Texas
-
Austin, Texas, Verenigde Staten, 78712
- The University of Texas at Austin
-
Houston, Texas, Verenigde Staten, 77030
- Baylor College of Medicine
-
Southlake, Texas, Verenigde Staten, 76092
- GI Alliance - Southlake
-
-
Utah
-
Ogden, Utah, Verenigde Staten, 84403
- Care Access Research Berkley
-
Salt Lake City, Utah, Verenigde Staten, 84132
- University of Utah
-
-
Virginia
-
Fairfax, Virginia, Verenigde Staten, 22031
- GCGA Physicians LLC
-
Lynchburg, Virginia, Verenigde Staten, 24502
- Gastroenterology Associates
-
-
Washington
-
Bellevue, Washington, Verenigde Staten, 98405
- GI Alliance
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Has an initial diagnosis of CD established within five years prior to screening by clinical and endoscopic evidence and corroborated by a histopathology report (if available).
- Has agreed to use the CDPATH™ tool.
- Has reliable access to the internet and is willing to answer electronic patient-reported outcomes (ePROs) throughout the study.
Exclusion Criteria:
- Has had known complications from CD including but not limited to: bowel stricture, CD-related intra-abdominal abscess, internal penetrating disease (known fistula other than perianal fistula), non-perianal surgery, bowel resection, or stricturoplasty. A perianal fistula or abscess without other signs of penetrating disease is allowed.
- Has had any non-CD-related abdominal surgery.
- Has received investigational biologic or nonbiologic agents for the treatment of CD in an investigational protocol. Approved biologic or nonbiologic agents for CD are allowed.
- Has previously used CDPATH™ or PROSPECT results to assess CD risk for complications.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Diagnostisch
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: CDPATH™
Participants with CD will be using CDPATH™ tool. Clinical data will be collected via an ongoing registry. Participants and health care provider (HCP)-reported outcomes data will be collected periodically once every 6 months for up to 36 months via electronic surveys. Two baseline blood samples will be collected at screening for CDPATH™ analysis. 1 additional sample will be collected for future potential biomarker analysis. |
Crohn's disease risk prediction tool.
Andere namen:
Three blood samples will be drawn. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage of Participants in Real-world Practice in Each Risk Category at Baseline Based on the CDPATH™ Tool Results
Tijdsspanne: Baseline (Day 1)
|
The risk profile of an individual participant with CD is the output of the CDPATH™ tool. Categories for CD includes low, medium, high risk of developing a CD complication within 3 years. |
Baseline (Day 1)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage of Participants with Specific Treatment Path and Choice Based on CDPATH™ Tool, Stratified According to Risk Category
Tijdsspanne: Up to 36 months
|
Treatment path (i.e., sequence over time) and choice, by low, medium and high risk, will be chosen to characterize treatment path and choice based on risk stratification. |
Up to 36 months
|
|
Change From Baseline in Decisional Conflict Scale (DCS) Score
Tijdsspanne: Baseline, then every 6 months up to 36 months
|
DCS is a validated electronic patient-reported outcome (ePRO) collected via electronically administered patient surveys. It measures personal perceptions of the following responses: uncertainty in choosing options, modifiable factors contributing to uncertainty such as feeling uninformed, unclear about personal values and unsupported in decision making, and effective decision making such as feeling the choice is informed, values-based, likely to be implemented and expressing satisfaction with the choice. DCS involves answering 11 questions of PRO, of which 10 questions can be answered as yes (score = 0) or unsure (score = 2) or no (score =4). The total score will range from 0 to 40. Higher score indicates higher decisional conflict. |
Baseline, then every 6 months up to 36 months
|
|
Change From Baseline in Work Productivity and Activity Impairment Questionnaire - CD Version (WPAI-CD) Score
Tijdsspanne: Baseline, then every 6 months up to 36 months
|
WPAI-CD is a validated ePRO collected via electronically administered patient surveys. It consists of six questions that evaluate 4 domain scores: absenteeism (i.e., work time missed), presenteeism (i.e., reduced work productivity), overall work impairment, and activity impairment. Scores are expressed as a percentage of impairment, where higher scores indicate greater impairment and reduced productivity. The total score ranges from 0 (no impairment) to 100% (total loss of work productivity). |
Baseline, then every 6 months up to 36 months
|
|
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health Scale Score
Tijdsspanne: Baseline, then every 6 months up to 36 months
|
PROMIS Global Health scale is a validated ePRO collected via electronically administered patient surveys. It is a 10-item PRO measuring the overall evaluation of one's physical and mental health. The total score ranges from 0 to 100. The final score will be represented by the T-score metric, in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. A higher PROMIS T-score represents more of the concept being measured (higher Global Health score indicate better health). |
Baseline, then every 6 months up to 36 months
|
|
Patient-Reported Satisfaction and Experience Score with the CDPATH™ Tool
Tijdsspanne: Up to 36 months
|
Participant's satisfaction and experience with the CDPATH™ tool will be assessed based on 15 questions. Negative responses/lower score to/in these questions indicates less satisfaction whereas positive responses/higher score indicates satisfaction with the tool. |
Up to 36 months
|
|
Number of Participants with Clinical Outcomes
Tijdsspanne: Up to 36 months
|
Participants with clinical outcomes describing the disease burden based on treatment path and controlling for risk strata will be reported. |
Up to 36 months
|
|
Percentage of Participants with Healthcare Resource Utilization
Tijdsspanne: Up to 36 months
|
Healthcare resource includes healthcare provider (HCP) visits/referrals, visit to emergency room, hospitalizations, surgery, new CD-related complications, and diagnostic evaluations (e.g., imaging, colonoscopy, etc.). |
Up to 36 months
|
|
Change from First Assessment in Health Care Provider (HCP)-reported Assessment of the Feasibility and Usability of the CDPATH™ Tool
Tijdsspanne: First assessment (6 months after HCPs first enrolled participant) up to HCP leaves the study or the study ends (up to 36 months)
|
HCP-reported CDPATH™ satisfaction data will be collected directly from HCPs via electronically administered HCP surveys and entered into the eCRF. HCPs will be queried regarding their satisfaction and experience with the general process, the ease of incorporating the tool in their everyday practice, and the impact of the tool on their treatment recommendations and participant communications. For the 6 questions, HCP will rate on 1-5 scale where, 1=strongly disagree and 5=strongly agree. For remaining 4 questions, written feedback from HCP will be consider. Overall positive responses will indicate higher feasibility and usability. |
First assessment (6 months after HCPs first enrolled participant) up to HCP leaves the study or the study ends (up to 36 months)
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Study Director, Takeda
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Darmziekten
- Ziekten van het spijsverteringsstelsel
- Gastro-intestinale aandoeningen
- Gastro-enteritis
- Inflammatoire darmziekten
- Ziekte van Crohn
- Onderzoekstechnieken
- Exemplaarbehandeling
- Klinische laboratoriumtechnieken
- Diagnostische technieken en procedures
- Diagnose
- Buren
- Chirurgische procedures, operatief
- Bloedspecimenverzameling
Andere studie-ID-nummers
- Vedolizumab-4015
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD-toegangscriteria voor delen
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- ICF
- MVO
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .